Morgan Stanley
EPRX

Morgan Stanley’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Morgan Stanley’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63.9K Buy
+8,820
New +$71K ﹤0.01% 6323

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley's EPRX Position: Q1 2026 in Review

Morgan Stanley opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q1 2026: 8,820 shares worth $63.9K. The stake represents ﹤0.01% of the portfolio and ranks #6323 among its holdings.

54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Morgan Stanley held 8,820 shares of Eupraxia Pharmaceuticals worth $63.9K as of Q1 2026.
  • Eupraxia Pharmaceuticals was a new Morgan Stanley position in Q1 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6323 holding.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.